been undertaken. An ophthalmologist suspected some impaired vision affecting the upper temporal quadrants; otherwise the eyes were normal. Because of recent activity, the tumour was given a dose of 4,300 rads with cobalt y-rays in twelve fractions over twenty-three days; estimated to be equivalent to about 4,500 rads given in twenty fractions over twenty-eight days using orthovoltage X-rays.
After satisfactory clinical remission the patient developed defective vision in one eye about fourteen months later. Exploratory craniotomy for suspected recurrence revealed no evidence of tumour, but atrophy of the optic tracts, regarded as secondary to radiation damage. There was no evidence of injury to other related structures.
Since this episode Jackson Richmond (1958), Crompton & Layton (1961) , Bignami et al. (1963) and Almquist et al. (1964) have reported other cases of radiation damage not only to the optic chiasma, but also severe and fatal damage to the related hypothalamic region, following doses of radiation to the pituitary of similar magnitude.
Almquist et al. (1964) comment on the relative radioresistance of the optic chiasma and tracts in contrast to the hypothalamus and white brain tissue and -refer to doses of about 100,000 r n-radiation, from implanted radio-yttrium seeds which were required to cause optic tract damage in monkeys. They consider that estimates of radiation dosage which produce radionecrosis of the optic nerve should remain open pending further investigations.
A case of optic nerve damage only, from external irradiation, has been reported by Lawrence et al. (1963) two years after ablation of the pituitary for breast cancer, using a narrow beam of ac-particles from a 900 MeV accelerator. Pituitary doses of about 15,000 rads are given in six treatments over eleven days, which may, by estimate, amount to four or five times the maximum equivalent dose given by X-or y-rays to a pituitary adenoma.
These workers have also irradiated the pituitary with a-particles for acromegaly and Cushing's disease, but the -fuil -value *of' this method, involving the use of very costly equipment, has yet to be assessed.
Experience with a relatively small number of patients confirms that most cases of pituitary tumour sent for radiotherapy are chromophobe adenomata. Corroboration by Horrax (1958) and Sheline et al. (1964) of the earlier findings of Henderson (1939) , that irradiation after surgery significantly increased the control rate, suggests that the combined attack is still to be preferred to surgery alone. There is as yet insufficient evidence of their radiosensitivity to warrant irradiation only of these adenomata, in preference to surgery: this however, may not apply with the same force to eosinophil tumours.
Although response to irradiation of pituitary adenomata increases with size of dose, a slight risk of radiation damage to the hypothalamic region and optic tracts seems to exist when doses exceed the equivalent of about 4,500 rads delivered to the gland with orthovoltage X-rays in twenty fractions over twenty-eight days. A maximum dose of 3,750 r (3,650 rads) over a similar period as suggested by Jackson Richmond (1958) appears reasonably safe, but might be raised slightly when employing cobalt y-rays, or equivalent high energy radiation.
Full cancericidal doses, risking morbidity, would be justifiable in treating malignant tumours.
Pituitary adenomata associated with Cushing's disease have not been treated in recent years by external irradiation.
Professor A P M Forrest, Dr F C Greenwood, Dr H J Stewart, Dr J P Thomas, Mr R G Wood, Dr (Forrest 1965 had occasional moisture of the nose, which could be due to a transient rhinorrhea.
The symptoms of the disease in these 8 patients were variable, mainly including headache, skin changes, and sweating. Two patients had lactorrhcea, and one severe symptoms of carpal tunnel compression. Relief of symptoms has also been variable, but improvement in headache has been most noticeable and has occurred in 5 out of 6 patients. Changes in appearance have not been marked although soft tissue regression, as estimated by reduction in hand volumes, has occurred in 3 patients. Inorganic phosphate levels in the serum have also generally fallen.
Six patients were euthyroid at the time of implant and have remained so. Two were thyrotoxic; in neither has this been influenced by the implant. In one (J S) serial estimations of protein-bound iodine in the serum were carried out. As the level was unaffected by the implant, subsequent iodine-131 therapy was required. In this patient headache has been relieved. Despite these changes, her thyrotoxicosis was unaffected. Protein-bound iodine, which in September 1960 was 13-6 pg/100 ml remained high and was 14-0 pg/100 ml in January 1961. She was then started on antithyroid drugs which have controlled her hyperthyroidism.
Two patients, whose symptoms were unaffected by the implantation of yttrium, have had second implants, one with yttrium and gold, the other with gold alone. In one, some relief of symptoms followed the second implant.
It is clear that, although the implantation of yttrium-90 may benefit some aspects of the acromegalic syndrome, the results are-inconclusive and variable. This may be due to the limited range of the particles which cannot penetrate to all parts of the asymmetrically enlarged gland and thus may spare considerable areas of secreting tumour tissue. We are now using implants of gold-198 alone, two small platinum-screened seeds being placed on the floor of the fossa, the dose being calculated to give not more than 10,000 rads to the region of the diaphragma (Joplin et al. 1961) (Fig 3) . The seeds are introduced through two small cannulk inserted through the nose. As gold-198 is a y emitter the minimum dose delivered to all parts of the pituitary should be at least 10,000 rads. According to Lawrence et al. (1963) but in all they are increased (Fig 4) . There is lack of the normal variation which follows fasting.
In the 8 patients we have studied, there has been little correlation between the concentration of growth hormone in the plasma and clinical and biochemical indices of activity. Symptoms such as headache, weakness, sweating and lactorrhoea are not more severe when the level of growth hormone is high. Changes in appearance seem more marked in patients with high levels (Fig 5) . Neither are the following apparently related to the growth hormone concentration (Fig 6): (1) The extent of bone changes (osteoporosis, tufting, inorganic P). (2) grossly enlarged fossa may be associated with a low and a normal-sized fossa with an excessively high level (Fig 7) . If, as it appears, one cannot assess activity on clinical grounds alone, the only certain guide to successful treatment is restoration of normal levels of circulating growth hormone. Repeated treatment may be necessary and, for this purpose, we have designed a small removable source of cobalt-60 which can be placed in the fossa for a variable time. The dose can be accurately estimated after the source of radiation is in place and repeated doses given, if necessary, by further insertion of the unit. The first was a 35-year-old woman who had, in 1952, a left, and in 1954 a partial right, adrenalectomy. These operations, and subsequent radiotherapy to the pituitary, failed to control the disease and, when referred to us in 1962, she had florid signs of increased cortisol secretion. Pituitary dependence was confirmed biochemically. She was also deeply pigmented and had an enlarging sella. The implantation of yttrium-90 by the screw technique did not lead to any improvement, either clinically or biochemically, and she remained pigmented. Nine months later, in August 1963, the pituitary was re-implanted with 26-2 mc of gold-198. This has been followed by remission of the syndrome, disappearance of pigmentation and reduction of the levels of circulating MSH in the peripheral blood (Fig 8) .
The second patient with a pituitary tumour and Cushing's syndrome has only recently been treated, 48 mc of gold-198 being inserted into her enlarged pituitary fossa.
Adrenal Hyperplasia ofNon-Cushing Type This patient, who has previously been described (Thomas 1962) , was a young woman aged 24 years, who had amenorrhoea from the age of 18 years, increase in weight and thinning of the hair. The pituitary fossa was enlarged and there was increased excretion of 17-oxosteroids associated with a normal level of pregnanetriol and 17-hydroxycorticosteroids in the urine. Yttrium implant (10 mc) was carried out on January 16, 1963 and has been followed by loss of weight and recent return of menstruation. No further enlarge- Non-endocrine Tumours Only two patients with non-endocrine tumours of the pituitary have been treated by implantation, both with yttrium-90. One died post-operatively and at post-mortem was found to have a large cyst of the sella transfixed by the two yttrium screw units. The other patient had an yttrium implant without complication.
Conclusions
The implantation of yttrium-90 by the screw technique is a reliable, safe and simple method to attempt pituitary ablation in patients with advanced malignant disease. Yttrium implant is less satisfactory in the treatment of pituitary tumours and, in common with others (Joplin et al. 1961 (Fig 1) .
Chromophobe adenomata of the pituitary are essentially different in this respect. When they impinge upon nervous tissue they invaginate rather than invade (Fig 2) . Chromophobe adenomata have been very adequately covered from the morbid anatomical and histological aspects by Kernohan & Sayre (1956) .
Small, clinically silent adenomata, composed of chromophobe cells of the pars anterior of the pituitary, are not uncommon. Larger adenomata, which usually first betray themselves clinically by pressure on the normal gland and the production of hypopituitarism, are histologically either (1) of diffuse type; or (2) of sinusoidal type, very similar in arrangement to normal pituitary, with numerous thin walled vessels; or (3) of papillary type, or a mixture of types. There is no correlation between histological type and behaviour. In biopsies some eosinophil cells are often seen amongst the chromophobes so that the tumours are often mixed rather than pure chromophobe.
The highly vascular nature of many of these tumours makes-it-not surprising that minor or major haemorrhage may occur into the tumour, before treatment, or major hemorrhage into the tumour may be the cause of death following biopsy (Fig 3) . Cyst formation, sometimes associated with hemorrhage, can occur as a part of the life history of an adenoma. Anaplasia of the tumour cells and mitoses may be present, but there does not appear to be any significant difference in behaviour between such tumours and those with a simpler histological appearance. (1) The tumour may rise up through the aperture in the diaphragma sells and press against and distort the optic chiasm and cause disturbance of vision. Above the optic chiasm and optic nerves lie the anterior communicating and anterior cerebral arteries. Sometimes an optic nerve is pressed upwards by a pituitary adenoma against a pulsating anterior cerebral artery. The result is.
